title: Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases.
abstract: Peripheral cytopenias are common in patients with agnogenic myeloid metaplasia (AMM). They are an important cause of morbidity and mortality, and their treatment is difficult. We report on 4 patients with AMM and severe cytopenia treated with danazol (400-600 mg/ day). Three of them became independent of red blood cell (RBC) transfusion, while the other had a slight reduction in RBC requirement. In addition, correction of thrombocytopenia and disappearance of splenomegaly were observed in 1 and 2 patients, respectively. No side effects were observed. In our experience, danazol appears effective and safe in the subset of patients with AMM whose disease is mainly characterized by bone-marrow failure. These data warrant further studies to evaluate this treatment and explore its mechanism of action.
authors.affiliation: Service d'Hématologie, Hôtel-Dieu, Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Lévy
authors.forename: A
authors.initials: A
authors.lastname: Bourgarit
authors.forename: A
authors.initials: A
authors.lastname: Delmer
authors.forename: O
authors.initials: O
authors.lastname: Legrand
authors.forename: M
authors.initials: M
authors.lastname: Baudard
authors.forename: B
authors.initials: B
authors.lastname: Rio
authors.forename: R
authors.initials: R
authors.lastname: Zittoun
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D003131:Combined Modality Therapy; D003613:Danazol / Q000627:therapeutic use*; D017707:Erythrocyte Transfusion / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy*; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology
chemical_list: D003613:Danazol